Spero治疗 SPRO 深 沪
等待开盘 02-04 09:30:00 美东时间
2.175
-0.055
-2.47%
华盛通- 最 高2.29
- 今 开2.21
- 成交量 8.75万股
- 最 低 2.175
- 昨 收 2.23
- 总市值 1.23亿
- 52周最高 3.22
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 0.5052
- 委 比 52.36%
- 总股本 5633.93万
- 历史最高 23.639
- 量 比 1.35
- 振 幅 5.16%
- 历史最低 0.5052
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics
Spero Therapeutics ( ($SPRO) ) has provided an update. On December 19, 2025, Sp...
2025-12-19 21:48
Spero Therapeutics Announces GSK Files New Drug Application Resubmission to FDA For Tebipenem HBr To Treat Complicated Urinary Tract Infections
Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today
2025-12-19 21:13
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
On November 3, 2025, Spero Therapeutics granted 90,000 RSUs to a new employee under its 2019 Inducement Plan. The RSUs vest over four years, starting December 1, 2025, contingent on continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) to attract new hires.
2025-11-28 13:00
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
<p>Spero Therapeutics announced positive results from the Phase 3 PIVOT-PO trial of tebipenem HBr for complicated urinary tract infections (cUTI), showing non-inferiority to intravenous imipenem-cilastatin. The company expects GSK to submit FDA filing by Q4 2025, with a regulatory decision anticipated in 2H 2026. Spero reported a net loss of $7.4 million for Q3 2025, with cash reserves of $48.6 million expected to fund operations into 2028. The S...
2025-11-13 21:05
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, announced it will release its third quarter 2025 financial results and provide a business update on November 13 after market close. The company does not plan to host a conference call.
2025-11-04 21:05
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Spero Therapeutics and GSK announced positive phase 3 results for oral tebipenem HBr in treating complicated urinary tract infections (cUTIs), showing non-inferiority to IV imipenem-cilastatin. The trial met its primary endpoint with tebipenem achieving a 58.5% success rate vs 60.2% for IV treatment, with comparable safety profiles. Data were presented at IDWeek 2025 and will support regulatory filings. If approved, tebipenem HBr would be the fir...
2025-10-21 06:00
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
Spero Therapeutics will present tebipenem HBr study results at IDWeek 2025, highlighting its Phase 3 trial success for treating complicated urinary tract infections. The oral presentation and posters will discuss efficacy, safety, and in vitro activity against bacterial infections. Tebipenem HBr, an oral carbapenem, has received FDA designations and is being developed with GSK. The presentation will take place on October 20 and 21 in Atlanta.
2025-10-14 12:00
Spero Therapeutics Q2 EPS $(0.03) Beats $(0.38) Estimate, Sales $14.189M Up From $10.197M YoY
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.38) by 92.11 percent. This is a 90.91 percent increase over losses of $(0.33) per share
2025-08-13 04:03
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
Spero Therapeutics announced the early termination of its Phase 3 PIVOT-PO trial for tebipenem HBr in treating complicated urinary tract infections (cUTI) due to demonstrated efficacy. The company plans to submit trial data to the FDA by mid-2025. Financially, Spero reported a net loss of $1.7 million for Q2 2025, with collaboration revenue from GSK contributing significantly. The company anticipates sufficient funding through 2028. Tebipenem HBr...
2025-08-12 20:01
